PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29277802
OWN - NLM
STAT- MEDLINE
DCOM- 20180104
LR  - 20180104
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Value of Diaphragmatic Surgery During Interval Debulking Surgery.
PG  - 411-416
AB  - BACKGROUND/AIM: The aim of this study was to assess the value of diaphragmatic
      surgery to achieve optimal debulking in patients with advanced ovarian cancer
      treated by neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: This is a
      retrospective review of the medical records of 182 patients. Diaphragmatic
      surgery was performed during interval debulking surgery (IDS) in 74 patients
      between January 2002 and December 2014. The patients were divided in 2 groups:
      with or without histological residual diaphragmatic disease. The time-course of
      serum CA125 levels, cytoreductive outcome, overall survival (OS) and relapse-free
      survival (RFS) were analyzed. Patients without diaphragmatic peritonectomy (DP)
      during IDS were included in the survival analysis. RESULTS: One hundred
      thirty-two (72.5%) patients had FIGO stage III disease and 43 (23.6%) patients
      had stage IV disease. Histological examination of DP was positive in 45 patients 
      and negative in 29 patients. CA125 normalization after the 3rd cycle of NAC was
      significantly associated with negative DP. OS tended to be higher in the
      DP-negative group (37.8 months vs 19 months, p=0.1). Median OS was 40.7 months in
      the case of IDS without DP and 22 months in the case of IDS with DP (p=0.048).
      CONCLUSION: Evaluation of residual diaphragmatic disease can be difficult after
      NAC. The CA125 tumor marker appears to be a useful tool to define the indications
      for DP. Diaphragmatic surgery after NAC may be of limited value.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Pelissier, Aurelie
AU  - Pelissier A
AD  - Department of Oncologic Surgery, Centre Rene Huguenin, Institut Curie, Saint
      Cloud, France [email protected]
FAU - Franke, Oona
AU  - Franke O
AD  - Department of Oncologic Surgery, Centre Rene Huguenin, Institut Curie, Saint
      Cloud, France.
FAU - Darai, Emile
AU  - Darai E
AD  - Department of Gynecology, Hopital Tenon, Paris, France.
FAU - Houvenaeghel, Gilles
AU  - Houvenaeghel G
AD  - Department of Oncologic Surgery, Institut Paoli-Calmettes, Marseille, France.
FAU - Chereau, Elisabeth
AU  - Chereau E
AD  - Department of Oncologic Surgery, Institut Paoli-Calmettes, Marseille, France.
FAU - Rouzier, Roman
AU  - Rouzier R
AD  - Department of Oncologic Surgery, Centre Rene Huguenin, Institut Curie, Saint
      Cloud, France.
AD  - Versailles-St-Quentin-en-Yvelines University: Risques cliniques et securite en
      sante des femmes et en sante perinatale, Versailles, France.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Interleukin-5 Receptor alpha Subunit)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Biomarkers, Tumor/*blood
MH  - Cytoreduction Surgical Procedures/*methods
MH  - Diaphragm/*surgery
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Interleukin-5 Receptor alpha Subunit/*blood
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Ovarian Neoplasms/drug therapy/pathology/*surgery
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Young Adult
OTO - NOTNLM
OT  - *Ovarian carcinoma
OT  - *diaphragmatic surgery
OT  - *neoadjuvant chemotherapy
EDAT- 2017/12/27 06:00
MHDA- 2018/01/05 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/09 00:00 [received]
PHST- 2017/10/23 00:00 [revised]
PHST- 2017/10/27 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/05 06:00 [medline]
AID - 38/1/411 [pii]
AID - 10.21873/anticanres.12237 [doi]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):411-416. doi: 10.21873/anticanres.12237.